UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028974
Receipt number R000033089
Scientific Title Molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia
Date of disclosure of the study information 2017/10/01
Last modified on 2018/09/25 10:51:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia

Acronym

Molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia

Scientific Title

Molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia

Scientific Title:Acronym

Molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia

Region

Japan


Condition

Condition

Diabetes
Functional dyspepsia

Classification by specialty

Gastroenterology Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To clarify the molecular pathological changes in the duodenal mucosa in patients with diabetes or functional dyspepsia

Basic objectives2

Others

Basic objectives -Others

To investigate the relationship between molecular pathological changes and upper abdominal symptoms

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To compare the expression of inflammatory markers and G protein-coupled receptors among diabetes, functional dyspepsia and control subjects

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Maneuver

Interventions/Control_1

Endoscopic biopsy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Three groups: Diabetes, Functional dyspepsia and Control.

1) Outpatients (age >= 20)
2)
(I) Diabetes: fasting blood sugar >= 126 mg/dl or casual blood glucose >= 200 mg/dl or HbA1c >= 6.5%.
(II) Functional dyspepsia: compatible with ROME III diagnostic criteria.
Requirements: [1] or [2] or both.
[1] Bothersome postprandial fullness after eating a normal amount of food >= two times/week.
[2] Unable to finish a normal amount of food due to early satiation >= two times/week.
(III) Control: The subjects who belongs to neither (I) nor (II).

3) The patients who can understand the contents of this study and give their entry agreement to this study by documents.

Key exclusion criteria

1) Patients with malignant diseases, gastrointestinal-organic diseases (malignancies, peptic ulcers, esophagitis, etc.) or systemic diseases (neurological disease such as Parkinson disease or metabolic diseases except for diabetes).
2) Patients with a history of surgery of the upper gastrointestinal tract (stomach and esophagus).
3) Patients with severe liver dysfunction and renal dysfunction.

4) Patients with mental disorder.

5) A pregnant woman, nursing mother or the subjects who hope pregnancy during this study term.

6) Patients whom doctors judged unsuitable as objects for this study.

7) Patients with H. pylori eradication within 6 months.

8) Patients having the following medicines: prokinetic drugs, H2 blocker, proton pump inhibitor, gastric-mucosal protectant, prostaglandin, NSAIDs, anti-depressants, anti-anxiety agents, sleep inducer, anti-psychotics drugs.

However, the patients, who can discontinue those medicines for two or more weeks before study start, can participate in this study.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroto Miwa

Organization

Hyogo College of Medicine

Division name

Division of Gastroenterology, Department of Internal Medicine

Zip code


Address

1-1, Mukogawa, Nishinomiya, Hyogo

TEL

0998-45-6662

Email

miwahgi@hyo-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hirokazu Fukui

Organization

Hyogo College of Medicine

Division name

Division of Gastroenterology, Department of Internal Medicine

Zip code


Address

1-1, Mukogawa, Nishinomiya, Hyogo

TEL

0998-45-6662

Homepage URL


Email

hfukui@hyo-med.ac.jp


Sponsor or person

Institute

Hyogo College of Medicine

Institute

Department

Personal name



Funding Source

Organization

Hyogo College of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 08 Month 15 Day

Date of IRB


Anticipated trial start date

2017 Year 09 Month 19 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 09 Month 02 Day

Last modified on

2018 Year 09 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033089


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name